Pediatric endocrinologist Dr. Casey Berman says GLP-1s may help children reduce their risk of developing serious health ...

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

A new report from The Center for Medicine in the Public Interest (CMPI) warns that regulators are failing to stop the illegal ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

National Weight Loss Doctor Scott Masey joined Bloom Health Club to explain what GLP-1 drugs really do, and what most people aren’t being told. “These meds don’t just help with ...

GLP-1 drugs like Ozempic and Mounjaro helped men with low testosterone raise their levels without hormone replacement in a ...

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

The U.K. biopharmaceutical giant’s plans include a proposal for a new drug substance manufacturing center focused on ...

West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.